Traitements médicaux guidés par la biologie en pathologie mammaire

The advances in biologic analyses based on gene expression profiling have allowed the classification breast cancers into four different diseases. Also, molecular analyses have allowed the identification of a number of candidate therapeutic targets. Such identification requires, now, the evaluation of each targeted agent in biologically-selected populations. Such changes in the model of drug development induce a number of implications. First, targeted agents will have to be developed for rare molecular diseases. Second, such model of development will require the launch of bioassay for each molecular alteration. In this review, we will first present the most frequent & quot;targetable" genomic alterations observed in breast cancers. Then, we will discuss the implications in terms of development of targeted agents.